vida: extract claims from 2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap

- Source: inbox/queue/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md
 scope: causal
 sourcer: Clinical Trial Vanguard
-related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism"]
 ---
 
 # GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
 
 The GLP-1 psychiatric safety paradox resolves through population stratification rather than dismissing either signal. Clinical trials and cohort studies systematically exclude patients with 'psychiatric instability' — specifically those with substance use disorders, prior mood episodes, or active anhedonia. This creates a bifurcated evidence base: (1) Trial/cohort populations over-represent metabolically driven psychiatric patients where GLP-1 appears protective (Swedish cohort showing reduced depression/anxiety in metabolic disease context), and (2) Pharmacovigilance captures real-world deployment including psychiatric comorbidity patients where GLP-1 may worsen symptoms. The highest-risk subpopulation is patients on concurrent psychotropic medications (antidepressants, benzodiazepines) showing OR 4.07-4.45 for suicidality reporting. The Novo Nordisk semaglutide MDD program (interim data late 2026) will provide the first prospective RCT evidence in psychiatric patients rather than metabolic patients with psychiatric comorbidities, serving as the decisive test of whether GLP-1 is genuinely antidepressant or whether the metabolic patient finding is a selection effect. The eating disorder signal is consistent with this framework: GLP-1 appetite suppression may trigger pathology in vulnerable patients systematically excluded from trials but present in real-world deployment.
+
+
+## Challenging Evidence
+
+**Source:** WHO guideline 2025-12-01, absence of psychiatric contraindications
+
+WHO guideline excludes only pregnant women as explicit contraindication, with no mention of psychiatric comorbidity screening despite documented eating disorder signal (aROR 4.17-6.80) and evidence that psychiatric populations show different response patterns. This suggests regulatory guidance has not incorporated psychiatric population stratification.

domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md

@@ -10,12 +10,17 @@ agent: vida
 scope: structural
 sourcer: Health Policy Watch
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
-supports:
-- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
-reweave_edges:
-- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
+supports: ["Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes"]
+reweave_edges: ["Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07"]
+related: ["regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence", "regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence", "eu-ai-act-medical-device-simplification-shifts-burden-from-requiring-safety-demonstration-to-allowing-deployment-without-mandated-oversight", "regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence", "clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance"]
 ---
 
 # Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 
 The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing high-risk AI requirements by up to 16 months and potentially removing them entirely for medical devices, arguing industry concerns about 'dual regulatory burden.' The same week, WHO warned that requirements for technical documentation, risk management, human oversight, and transparency would no longer apply by default to AI medical devices, creating a regulatory vacuum where 'clinicians will still be expected to use AI safely and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight.' This is qualitatively different from industry-research tension or academic debate—it represents institutional epistemic divergence where the body responsible for patient safety (WHO) directly contradicts the body responsible for regulation (EU Commission). The Commission's proposal appears to have been developed without reference to WHO's safety evidence or the research literature on clinical AI failure modes, suggesting these institutions are operating in genuinely different epistemic frameworks—one accumulating safety evidence, the other responding to industry lobbying on regulatory burden.
+
+## Supporting Evidence
+
+**Source:** WHO guideline 2025-12-01
+
+WHO issued global GLP-1 obesity guideline in December 2025 without eating disorder screening requirements despite pharmacovigilance signal (aROR 4.17-6.80) documented in literature 18+ months prior. Regulatory expansion occurred without integrating known safety signals into prescribing infrastructure.

domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md

@@ -10,7 +10,7 @@ agent: vida
 scope: structural
 sourcer: WHO
 supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence", "who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty"]
 ---
 
 # WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
@@ -29,3 +29,10 @@ The WHO's 'conditional' framing (versus 'strong' recommendation) acknowledges co
 **Source:** WHO Global Guideline, December 2025
 
 WHO issued conditional recommendation December 2025 with explicit equity and access concerns, while USPSTF maintains 2018 exclusion. The WHO conditionality is based on 'high current costs' and 'inadequate health system readiness' which directly impacts ACA mandatory coverage pathway that depends on USPSTF grade A or B recommendation
+
+
+## Extending Evidence
+
+**Source:** WHO news release 2025-12-01
+
+WHO December 2025 guideline is a conditional recommendation citing 'limited data on long-term efficacy and safety' and concerns about 'falsified and substandard medical products' requiring 'regulated distribution and prescription by qualified health care providers.' The conditional nature suggests WHO recognizes infrastructure gaps beyond clinical efficacy.

domains/health/who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Regulatory response gap where signal magnitude (aROR 4.17-6.80, highest psychiatric signal) is disproportionate to regulatory action (none)
+confidence: experimental
+source: WHO guideline news release 2025-12-01, VigiBase eating disorder signal literature 2024-2025
+created: 2026-05-04
+title: WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
+agent: vida
+sourced_from: health/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md
+scope: structural
+sourcer: World Health Organization
+supports: ["regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence"]
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign-because-the-fda-drug-and-device-model-built-for-static-products-cannot-govern-continuously-learning-software", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap"]
+---
+
+# WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
+
+The WHO issued a global guideline on December 1, 2025, recommending GLP-1 receptor agonists (semaglutide and two other agents) for long-term obesity treatment in adults. The guideline news release identifies only one explicit population exclusion: pregnant women. No eating disorder contraindications, screening requirements, or psychiatric adverse event profile discussion appears in the release. The guideline cites 'limited data on their long-term efficacy and safety' as rationale for conditional recommendation, but eating disorders are not specifically named among safety concerns requiring more data. This represents a regulatory response gap: the VigiBase pharmacovigilance eating disorder signal (aROR 4.17-6.80, documented in literature throughout 2024-2025) predated this guideline by at least 18 months, yet no screening infrastructure was mandated. The contrast is stark when compared to the suicidality signal (aROR 1.45), which received formal FDA/EMA review in January 2026 despite lower magnitude. The eating disorder signal represents the highest psychiatric adverse event signal for GLP-1s, yet it has generated essentially no regulatory response at the global health authority level. This creates a world where 43M+ Americans are on GLP-1s, the WHO has recommended broad global adoption, and no formal screening requirement for eating disorder history exists in prescribing guidance.

inbox/archive/health/2025-12-01-who-glp1-obesity-guideline-eating-disorder-gap.md

@@ -7,10 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: official-guidance
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-04
 priority: medium
 tags: [glp1, who, guideline, obesity, global, eating-disorders, regulatory-gap]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content